Clinical trial NCT00121186 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: fludarabine phosphate, melphalan, methotrexate, tacrolimus
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of lymphoma of 1 of the following types:

               -  Diffuse large B-cell lymphoma

               -  Follicular lymphoma

                    -  Grades 1, 2, or 3

               -  Primary mediastinal lymphoma

               -  Mantle cell lymphoma

               -  Small lymphocytic lymphoma

               -  Hodgkin's lymphoma

               -  Transformed lymphoma

          -  Relapsed after prior autologous bone marrow transplantation (BMT)

               -  More than 180 days post BMT

          -  Received ≥ 1 course of chemotherapy after BMT relapse

               -  Achieved a complete response OR a partial response to chemotherapy

                    -  Largest residual tumor dimension ≤ 2 cm

          -  No clinical or laboratory evidence of CNS involvement by lymphoma

          -  HLA-identical donor available, meeting 1 of the following criteria:

               -  Sibling donor with 5/6 or 6/6 alleles matching by genotyping

                    -  No monozygotic identical twins

               -  Unrelated donor with 10/10 alleles matching by genotyping

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  LVEF ≥ 40% by MUGA or 2-D echocardiogram (2-D ECHO)

          -  No significant cardiac abnormalities by MUGA or 2-D ECHO

          -  No uncompensated coronary artery disease by ECG or physical exam

          -  None of the following within the past 6 months:

               -  Myocardial infarction

               -  Unstable angina

               -  Uncontrolled atrial fibrillation

          -  None of the following within the past 3 months:

               -  Severe peripheral vascular disease

               -  Venous stasis ulcers

               -  Deep venous or arterial thrombosis

          -  No uncontrolled hypertension

        Pulmonary

          -  DLCO (corrected) and total lung capacity ≥ 40% of predicted

          -  No requirement for continuous supplemental oxygen

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No AIDS

          -  No active bacterial, viral, or fungal infection

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No history of uncontrolled seizures

          -  No diabetic ulcers within the past 3 months

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

          -  No more than 1 prior bone marrow transplantation

        Chemotherapy

          -  See Disease Characteristics

          -  More than 21 days since prior chemotherapy and recovered

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  More than 4 weeks since prior major surgery except placement of a venous access device